Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Core Insights - Geron Corporation has announced a strategic restructuring plan aimed at long-term value creation for patients and shareholders while improving financial discipline [2][3] - The restructuring is expected to lead to a one-third reduction in the current workforce of approximately 260 employees, with significant savings anticipated in operating expenses for 2026 [3] Group 1: Restructuring Plan - The restructuring plan is designed to streamline the organizational structure and advance the company's strategy [3] - Initial projected full year 2026 operating expenses are expected to be lower than those projected for 2025, with savings beginning in the first quarter of 2026 [3] - The restructuring will incur cash-based expenses, with further details to be provided in a Current Report on Form 8-K [3] Group 2: Business Focus - The company remains focused on driving the commercial growth of RYTELO in the U.S. and exploring opportunities for its availability outside the U.S. [3] - Geron is continuing to advance its Phase 3 IMpactMF trial, which is critical for the development of its lead product, RYTELO [3][4] - RYTELO (imetelstat) is a first-in-class telomerase inhibitor approved for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) [4]